drugset / Trial / NCT06664970
A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, multicenter, open label cohort study involving MDS/MPN patients. The enrolled patients have symptoms that require treatment, which are classified according to their clinical conditions as follows: those with MDS as the main manifestation are treated with Azacitidine combined with Selinexor; For those with MPN as the main manifestation, treatment with Selinexor combined with Ruxolitinib is used.
Timeline
- Start
- 2024-11-06
- Primary completion
- 2025-09-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Ruxolitinib | Small molecule | 10 mg | — |
| Subject | Ruxolitinib | Small molecule | 15 mg | — |
| Subject | Selinexor | Other / unclassified | 40 mg | — |
| Subject | Selinexor | Other / unclassified | 60 mg | — |